Oct 20 (Reuters) - AstraZeneca said on Tuesday that it is working with Oracle to use AI and real-world data to identify ...

Oct 20 (Reuters) - Amgen and AstraZeneca said on Tuesday their asthma drug helped reduce swallowing difficulties and achieved ...

AstraZeneca is working with Oracle to investigate the use of artificial intelligence (AI) and real-world data to help identify eligible patients for clinical trials. The two companies also plan to ...

Oracle kicked off the year by launching its Oracle Life Sciences AI Data Platform, which it touted as using generative AI, ...

AstraZeneca and Oracle signed a non-binding AI deal on Oct. 20, 2026; first program with M42 targets uncontrolled ...

AstraZeneca and Oracle will use AI and real-world health data to find trial patients sooner, starting with a hypertension ...

AstraZeneca and Oracle team up on AI, aiming to speed up clinical trials and improve patient care pathways, with the first ...

The AstraZeneca collaboration is a credible wedge into recurring, software-like healthcare AI (Cerner upgrades + trial ...

AstraZeneca and Oracle Health and Life Sciences have announced a global partnership aimed at connecting scientific research ...

Oracle today announced an agreement with AstraZeneca to explore how AI and real-world data can help clinicians identify eligible patients for clinical trials, accelerate evidence generation, and bring ...

AstraZeneca just locked in a price to own 12% of Summit Therapeutics that the open market refuses to match, and two clinical deadlines in 2026 will determine whether Wall Street or the pharma giant ...

AstraZeneca (AZN) shares have been enjoying a strong bull run ever since falling to a low of $55 in mid-October last year - their lowest value since April 2021. Across a five-year period, overall ...